Dong-A Socio Holdings Co., Ltd. (KRX:000640)

Market Cap	640.31B
Revenue (ttm)	1.33T
Net Income (ttm)	58.02B
Shares Out	6.44M
EPS (ttm)	9,011.65
PE Ratio	11.04
Forward PE	7.25
Dividend	1,650.49 (1.65%)
Ex-Dividend Date	Mar 13, 2025

Volume	10,383
Average Volume	11,829
Open	101,800
Previous Close	103,000
Day's Range	99,800 - 102,400
52-Week Range	90,583 - 124,757
Beta	0.05
RSI	51.53
Earnings Date	May 2, 2025

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,530
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2024, Dong-A Socio Holdings's revenue was 1.33 trillion, an increase of 17.78% compared to the previous year's 1.13 trillion. Earnings were 58.02 billion, an increase of 0.06%.